30 DAY MORTALITY FOLLOWING ANDEXANET ALFA IN ANNEXA-4 COMPARED WITH PROTHROMBIN COMPLEX CONCENTRATE (PCC) THERAPY IN THE ORANGE STUDY FOR LIFE THREATENING NON-VITAMIN K ORAL ANTICOAGULANT (NOAC) RELATED BLEEDING

Life-threatening NOAC related major bleeding is associated with high mortality. Off-label PCC is currently recommended in some guidelines as well as the approved specific antidote, andexanet alfa (andexanet). There are no randomised controlled trials comparing these therapies and hence we undertook